Loading
An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD). ClinicalTrials.gov record last updated 2026-08-04: active not recruiting. Enrollment is actual at 10 participants. Primary completion is estimated at 2029-01-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/